Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Niagen BioscienceFRA:OCD1 67 Market Cap is €230.5 Mil as of Jul. 29, 2026. GuruFocus rates FRA:OCD1 with a GF Score™ of 67/100 and a GF Value™ of €3.98 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,421 Biotechnology companies, Niagen Bioscience ranks better than 62.28% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Niagen Bioscience's share price for the quarter that ended in Mar. 2026 was €3.5. Niagen Bioscience's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 79.5 Mil. Therefore, Niagen Bioscience's market cap for the quarter that ended in Mar. 2026 was €278.1 Mil.
Niagen Bioscience's quarterly market cap
declined
from Sep. 2025 (€649.1 Mil) to Dec. 2025 (€426.5 Mil) and
declined
from Dec. 2025 (€426.5 Mil) to Mar. 2026 (€278.1 Mil).
Niagen Bioscience's annual market cap
increased
from Dec. 2023 (€99.0 Mil) to Dec. 2024 (€402.1 Mil) and
increased
from Dec. 2024 (€402.1 Mil) to Dec. 2025 (€426.5 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Niagen Bioscience's Enterprise Value for Today is €174.3 Mil.
Niagen Bioscience (FRA:OCD1) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Niagen Bioscience Market Cap Related Terms
Niagen Bioscience Market Cap Historical Data
* Premium members only.
The historical data trend for Niagen Bioscience's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:OCD1 vs LCTX, IFRX, VRXA: Market Cap Comparison
For the Biotechnology subindustry, Niagen Bioscience's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Niagen Bioscience Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Niagen Bioscience's Market Cap distribution charts can be found below:
* The bar in red indicates where Niagen Bioscience's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Niagen Bioscience's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Niagen Bioscience (FRA:OCD1) has a Market Cap of €230.5 Mil as of Jul. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Niagen Bioscience and its competitors. According to the industry distribution chart, Niagen Bioscience ranks #536 out of 1421 companies in the Biotechnology industry, placing it in the top 37.7%.
Is Niagen Bioscience's Market Cap too high?
Niagen Bioscience's current Market Cap is €230.5 Mil. Based on the distribution chart, Niagen Bioscience ranks #536 out of 1421 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Niagen Bioscience has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Niagen Bioscience's Market Cap compare to LCTX and IFRX?
According to the Biotechnology industry distribution chart, Niagen Bioscience ranks #536 out of 1421 companies for Market Cap. This puts Niagen Bioscience in the upper half of its industry. The industry median Market Cap is 111.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 111.82, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Niagen Bioscience and its competitors. For the Biotechnology industry, the median Market Cap is 111.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Niagen Bioscience's current Market Cap is €230.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niagen Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Niagen Bioscience (FRA:OCD1) is currently considered Possible Value Trap. The stock's GF Value™ is €3.98, compared to a current price of €2.58 — trading 35.2% below its estimated fair value. The current Market Cap is €230.5 Mil. Niagen Bioscience's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Niagen Bioscience (FRA:OCD1), the current Market Cap is €230.5 Mil as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Niagen Bioscience (FRA:OCD1) Overvalued in 2026?
Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued.
The current stock price of €2.58 is trading 35.2% below its estimated GF Value™ of €3.98.
GuruFocus considers Niagen Bioscience to be Possible Value Trap.
Key valuation signals for FRA:OCD1:
Market Cap: €230.5 Mil
GF Value™: €3.98 vs. price of €2.58 (35.2% below fair value)
No single metric tells the full story. See the FRA:OCD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
67GF Score
Get the complete analysis for FRA:OCD1
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OCD1 has been successfully added to your 
